20 maj 2025
Trill Impact partners with Primutec to drive growth in the building envelope services market
Trill Impact has entered a partnership with Primutec, a leading Dutch and German building envelope services...
01 april 2025
Trill Impact the Swedish winner of SHE Index 2025
Trill Impact’s SHE Index score is 92.8. It is the highest score among the participating companies in...
08 mars 2025
Empowering Resilience: Frida Westerberg on Female Leadership and Cybersecurity’s Role in Society
Allurity, a cybersecurity service provider and a Trill Impact portfolio company since 2021, brings together...
07 mars 2025
Trill Impact has been awarded Best ESG Investment Fund: Impact Private Markets
We are thrilled to share that Trill Impact was awarded "Best ESG Investment Fund: Impact Private Markets"...
28 februari 2025
Trill Impact has been awarded as Impact Firm of the Year: Healthcare
We proudly announce that Trill Impact has been awarded "Impact Firm of the Year – Healthcare" in the...
05 december 2024
Trill Impact achieves top scores across all applicable modules in PRI's 2024 Assessment Report
Highest score possible, given to PRI signatories that demonstrate leading responsible investment practices.
12 november 2024
Impact Series
We are thrilled to announce the launch of the third season of our Impact Champion Program
19 september 2024
Trill Impact receives highest possible rating in BlueMarks Fund ID pilot program
Independent verification of Trill Impact’s Private Equity strategy.
03 september 2024
Trill Impact Ventures leads Soil Capital’s EUR 15m Series B financing round
Belgian start-up facilitating farmers’ transition to regenerative agriculture and issuing carbon certificates...
05 juli 2024
Trill Impact has closed its inaugural Ventures Fund, focusing on improved health and climate action
The closing enables continued growth for Trill Impact’s Ventures portfolio, backing innovative companies...
20 juni 2024
Trading in Trill Impact’s portfolio company Cinclus Pharma commences on Nasdaq Stockholm
The Swedish biopharmaceutical company has successfully raised capital for Phase 3 clinical development
13 maj 2024
Trill Impact Ventures co-leads USD 25 million series B financing round in May Health
Advancing novel treatment for women suffering from Polycystic Ovary Syndrome related infertility.